CAC
CEROW

Cowen and Company’s CERo Therapeutics Warrants CEROW Stock Holding History

Cowen and Company’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-737,168
Closed -$3.76K – 326
2024
Q3 		$3.76K Buy
737,168
+50,100
+7% +$832 ﹤0.01% 554
2024
Q2 		$13.8K Buy
687,068
+48,467
+8% +$2.84K ﹤0.01% 435
2024
Q1 		$43.6K Buy
638,601
+438,511
+219% +$26.7K ﹤0.01% 363
2023
Q4 		$4.7K Buy
200,090
+142,090
+245% +$4.43K ﹤0.01% 463
2023
Q3 		$4.15K Hold
58,000
– – ﹤0.01% 545
2023
Q2 		$3.54K Hold
58,000
– – ﹤0.01% 495
2023
Q1 		$2.32K Sell
58,000
-905
-2% -$41 ﹤0.01% 518
2022
Q4 		$2.54K Buy
+58,905
New +$3.1K ﹤0.01% 546

Other funds holding CEROW

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Cowen and Company's CEROW Position: Q4 2024 in Review

Cowen and Company sold out of CERo Therapeutics Warrants (CEROW) in Q4 2024, closing a stake of 737,168 shares — an estimated $3.76K sold.

Cowen and Company first reported a position in CEROW in Q4 2022 and held it in 8 quarters. The position peaked at $43.6K in Q1 2024. 26 funds tracked by Wall St. Rank hold CEROW as of Q4 2024.

  • Cowen and Company reported no remaining CERo Therapeutics Warrants position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 737,168 CERo Therapeutics Warrants shares in Q4 2024, an estimated $3.76K.
  • Cowen and Company first reported a position in CERo Therapeutics Warrants in Q4 2022 and held it in 8 quarters.
  • Cowen and Company's CERo Therapeutics Warrants position peaked at $43.6K in Q1 2024.
  • 26 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.